June 23, 2015.TapImmune (TPIV) Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients.The potential to treat ~85% of breast cancer patients with this HER2/neu therapeutic approach is significant. The successful completion of this HER2/neu vaccine Phase I study and the robust immune responses detected provides TapImmune with a second Phase II clinical candidate and an expanded clinical pipeline for the treatment of breast and ovarian cancer. It also further validates the technology and the approach developed at Mayo Clinic by Professor Keith Knutson."
